secwatch.observer — SEC 8-K summary
======================================

Issuer:     COGNITION THERAPEUTICS INC (CGTX)
CIK:        0001455365
Form:       8-K
Filed at:   2023-06-28T23:59:59+00:00
Accession:  0001104659-23-075552
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cognition Therapeutics announces positive Phase 2 SEQUEL topline results for CT1812 in Alzheimer's
--------------------------------------------------------------------------------

- Phase 2 SEQUEL study met primary safety and tolerability endpoints; CT1812 well-tolerated with no treatment-related SAEs.
- CT1812 showed numerical reduction in relative theta power vs placebo on qEEG, indicating positive impact on brain activity.
- Nominal statistical significance achieved for reduced relative theta in central brain region and for AECc brain connectivity measure.
- Study involved 16 adults with mild-to-moderate Alzheimer's; full results to be presented at upcoming medical meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923075552/0001104659-23-075552-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1455365/000110465923075552/tm2319819d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-075552

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer